Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus anlotinib in recurrent glioblastoma
ChiCTR2000039175Phase 2Recruiting
- Sponsor
- Tangdu Hospital
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab and anlotinib in glioblastoma (GBM), sponsored by Tangdu Hospital. Primary endpoint: Overall survival. Started Nov 2020; status: recruiting.
02
Drugs
toripalimabanlotinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000039175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039175.